Home  /  Resource Library  /  Improvement in parameters of hematologic and immunologic function and patient well-being in the phase III RESONATE study of ibrutinib vs ofatumumab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma

Improvement in parameters of hematologic and immunologic function and patient well-being in the phase III RESONATE study of ibrutinib vs ofatumumab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma

Study examined the well-being of patients participating in a clinical trial comparing Ibrutinib versus Ofatumumab for relapsed CLL.